SAB Biotherapeutics Inc (SABS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SAB Biotherapeutics Inc (SABS) has a cash flow conversion efficiency ratio of -0.111x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.78 Million) by net assets ($151.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SABS cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
SAB Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how SAB Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SAB Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SAB Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
US Gold Corp
NASDAQ:USAU
|
-0.095x |
|
Suzhou Iron Technology Co. Ltd. A
SHG:688329
|
0.053x |
|
Filatex India Limited
NSE:FILATEX
|
0.155x |
|
Octodec
JSE:OCT
|
0.036x |
|
Soren Acquisition Corp. Class A Ordinary Shares
NASDAQ:SORN
|
-0.002x |
|
LIFELINE SPAC I OYJ A EO1
F:0CD
|
N/A |
|
Super-Dragon Engineering Plastics Co. Ltd
SHE:301131
|
-0.004x |
|
ProCap Acquisition Corp Class A Ordinary Shares
NASDAQ:PCAP
|
-0.001x |
Annual Cash Flow Conversion Efficiency for SAB Biotherapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of SAB Biotherapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see SAB Biotherapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $151.49 Million | $-44.78 Million | -0.296x | +77.62% |
| 2024-12-31 | $25.97 Million | $-34.29 Million | -1.320x | -201.21% |
| 2023-12-31 | $57.30 Million | $-25.12 Million | -0.438x | +41.96% |
| 2022-12-31 | $31.06 Million | $-23.46 Million | -0.755x | -1565.54% |
| 2021-12-31 | $38.55 Million | $1.99 Million | 0.052x | -79.90% |
| 2020-12-31 | $39.01 Million | $10.00 Million | 0.256x | -93.58% |
| 2019-12-31 | $-2.31 Million | $-9.21 Million | 3.997x | -- |
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes … Read more